The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.

ABSTRACT:

SUBMITTER: Huang DT 

PROVIDER: S-EPMC8144687 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature